The tuberous sclerosis complex gene 2 (TSC2)/mammalian target of rapamycin (mTOR) pathway controls many cellular functions via phosphorylation of ribosomal protein S6 kinases (S6Ks). Alternative splicing and translation generate three S6K1 proteins. Although nuclear and cytoplasmic S6K targets are known, the nucleocytoplasmic localization of the S6K1 proteins has not been comparatively elucidated so far. We show that in primary fibroblasts p85 S6K1 is cytoplasmic, p70 can be found in both compartments and p31 is exclusively nuclear. As already known for p70 and p85, our data suggest that p31 is also a target of mTOR-mediated phosphorylation. Blocking mTOR kinase activity via rapamycin and its activation in TSC2 À/À cells and via TSC2 small interfering RNAs revealed that it regulates the localization of p70, but not of p85 and p31. The mTOR-dependent phosphorylation of p70 S6K1 at T389 is essential for its nuclear localization and exclusively hyperphosphorylated p70 S6K1 can be found in the nucleus. We further demonstrate this mTOR-controlled p70 S6K1 localization to be growth factor dependent. During the cell-cycle phosphorylation and nuclear localization of p70 S6K1 occur in mid G1 phase. We report that the different S6K1 proteins exhibit different nucleocytoplasmic localizations and that the TSC2/mTOR cascade not only regulates p70 S6K1 activity, but also its localization. These findings provide new important insights into the temporal and spatial dynamics of TSC2/mTOR/S6K regulation.
Introduction
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase having a central role within the insulin-signaling cascade regulating a wide variety of different cellular functions. Upstream of mTOR, the PI3K (phosphatidylinositol-3-kinase) regulates the activity of the oncogenic kinase Akt (also known as protein kinase B) via PDK1 (phosphoinositide-dependent kinase-1). Akt-mediated phosphorylation of the tuberous sclerosis tumor suppressor protein tuberin (encoded by tuberous sclerosis complex gene 2 (TSC2)) causes its functional inactivation and leads to enhanced mTOR activity. In mammalian cells two structurally and functionally distinct mTOR-containing complexes have been identified. mTORC1 is composed of mTOR, raptor and mLST8 and mTORC2 contains mTOR, rictor, mLST8 and sin1 (Yang and Guan, 2007; Wang and Proud, 2009; Sengupta et al., 2010) .
Whereas mTORC2 phosphorylates and activates Akt, the best-characterized phosphorylation targets and downstream effectors of mTORC1 are the eukaryotic initiation factor 4E-binding protein and the ribosomal protein S6 kinases (S6Ks). mTOR is known to phosphorylate and thereby activate p70 S6K1 at T389 and p85 S6K1 at T412. The mTOR-mediated phosphorylation status of p70 S6K1 T389 has been demonstrated to always correlate with p70 S6K1 kinase activity (Ruvinsky and Meyuhas, 2006; Shaw, 2008) .
Mammalian cells express S6K1, encoded by RPS6KB1, and S6K2, encoded by RPS6KB2. Due to alternative translation two isoform 1 S6K1 proteins are known to exist in mammalian cells: p85 S6K1 and p70 S6K1, which is identical to p85 S6K but lacks its first 23 amino acids (Meyuhas and Dreazen, 2010) . In addition, mammalian cells express a second S6K1 isoform spanning 316 amino acids (p31 S6K1) (Figures 1a and  b) . Overexpression of the alternative splicing protein SF2/ASF (also known as SFRS1) triggers predominant expression of p31 S6K1. It was demonstrated that the S6K1-splicing protein SF2/ASF is a proto-oncogene and that, although p70 S6K1 has little oncogenic potential, the alternatively spliced p31 S6K1 is sufficient to cause cell transformation and has a major role for the SF2/ASF-mediated cellular transformation phenotype (Karni et al., 2007; Fenton and Gout, 2011) .
S6Ks and RSKs (p90 ribosomal protein S6 kinases) are the two classes of kinases phosphorylating the ribosomal protein S6. S6 protein is dispersed throughout the cytoplasm and concentrated to the nucleoli within the nucleus, what is a consequence of the fact that eukaryotic ribosomes are assembled in the nucleolus before export to the cytoplasm. Besides S6, many other S6K substrates have been reported, including, for example, the cytoplasmic proteins eukaryotic elongation factor 2 kinase, eukaryotic translation initiation factor 4B, BAD, insulin receptor substrate, and mTOR (which is also located to the nucleus) and the nuclear proteins cAMP-responsive element modulator t, the 80-kDa subunit of the nuclear Cap-binding complex and S6K1 Aly/REF-like target (Ruvinsky and Meyuhas, 2006; Meyuhas and Dreazen, 2010) .
Although both, nuclear and cytoplasmic, S6K substrates have been reported, the nucleocytoplasmic localization of the three S6K1 proteins, p31, p70 and p85, has not been comparatively elucidated so far.
Using non-transformed, non-immortalized primary human fibroblasts we show here that p85 S6K1 is cytoplasmic, the p70 protein is localized to both, cytoplasm and nucleus, whereas p31 is nuclear. The p70 and p85 isoforms are known to be phosphorylated by mTOR. Our presented findings here suggest that p31 is also a target of mTOR-mediated phosphorylation. However, blocking mTOR activity via rapamycin does not affect the nucleocytoplasmic localization of p31 and p85, but triggers loss of nuclear p70 S6K1. Analyses of p70 S6K1 mutants, either phosphorylation defective or mimicking, demonstrated that phosphorylation of p70 S6K1 at T389 is essential for its nuclear localization. In primary cells only hyperphosphorylated p70 S6K1 can be detected in the nucleus. In agreement with this role of the mTOR pathway for the p70 S6K1 localization, activation of the mTOR cascade in TSC2 À/À fibroblasts or via TSC2-specific small interfering (si)RNAs selectively induces nuclear localization of the p70 protein. Although cytoplasmic p70 S6K1 protein can be detected in all phases of the mammalian cell cycle, this protein becomes nuclear only at mid G1 phase. TSC2 siRNA experiments revealed that this cell cycledependent nucleocytoplasmic localization of p70 S6K1 is controlled by the TSC2/mTOR pathway. Our data show for the first time that the S6K1 proteins are Figure 1 Distinct expression patterns of S6K1 isoforms p85, p70 and p31 in various cell types. (a) Schematic presentation of the S6K1 family of ribosomal protein S6 kinases. Alternative splicing of the primary transcript of RPS6KB1 results in the generation of two different isoforms, a longer one, spanning 525 amino acids (p85 S6K1) and a shorter one spanning 316 amino acids (p31 S6K1). An alternative translation start site in the N-terminus of splicing variant 1 (isoform 1) gives rise to an additional protein, the p70 S6K1, which is identical to p85 S6K1 but lacks its first 23 amino acids and therefore comprises 502 amino acids. Similar diversity including different isoforms is known for S6K2 as well as for the p90 ribosomal protein S6 kinases (RSKs), but is not outlined and discussed in detail here. (b) Schematic alignment of isoforms 1 and 2 of S6K1. p85 S6K1 and p70 S6K1 are almost identical except that the shorter form lacks the N-terminal 23 amino-acids extension of p85 S6K1 containing a suggested nuclear-localization-signal (NLS). Isoform 2 of S6K1 (p31 S6K1) is identical to p85 S6K1 for amino acids 1-195 but differs in the adjacent 121 amino acids (dashed box). The kinase domain of p70 and p85 S6K1 is only partially existent in p31 S6K1. The major phosphorylation sites known to drive full activation of p70 S6K1 (and the corresponding sites in p85 S6K1) are highlighted. (c) Four non-tumor mammary gland-derived cell lines and four established breast cancer cell lines were examined for the expression level of SF2/ASF (upper panel) and S6K1 isoforms p85, p70 and p31 (lower panels) via immunoblotting using indicated antibodies. The N-terminal anti-p70S6K1 antibody used here detects both transcript variants, p85/p70 and p31. Although detected in a single step on the same membrane, different exposures of p85/p70 and p31 are separately presented to overcome apparent differences in their expression ratio and to allow direct comparison between samples. (d) Experiments presented in (c) were repeated using four distinct bladder cancer cell lines and a corresponding nontumor derived cell line (nt). In addition, cells of different origin (different), including human non-transformed, non-immortalized IMR-90 fibroblasts and various immortalized and/or transformed cell lines were co-analyzed. (e) Immortalized NIH3T3 murine fibroblasts, primary IMR-90 fibroblasts and BT474 breast cancer cells, both of human origin, were analyzed for the expression pattern of S6K1 isoforms p85, p70 and p31 via immunoblotting using the aforementioned anti-p70S6K1 antibody directed against the Nterminus of S6K1 (left panel). In addition, same lysates were analyzed with a C-terminal p70 S6K1 antibody. A direct comparison of both immunodetections is separately presented (right panel). (f) BT474 and IMR-90 cells were treated with siRNAs specifically targeting human S6K1 and were examined for knockdown efficiency via immunoblotting using indicated antibodies. differently localized and that alternative splicing can be a mechanism resulting in different cytoplasmic/nuclear localization of proteins encoded by one gene. In addition, we demonstrate that the TSC2/mTOR cascade not only regulates the activity of p70 S6K1 via phosphorylation, but also its growth factor-and cell cycledependent nucleocytoplasmic localization. Our findings allow a better understanding of the temporal and spatial regulation of TSC2/mTOR and S6K1 activities.
Results
Nucleocytoplasmic localization of the S6K1 proteins p85, p70 and p31 The alternative splicing protein SF2/ASF is an oncogene responsible for the generation of p31 via splicing of S6K1 (Figures 1a and b ; Karni et al., 2007) . Western blot analyses revealed that compared with four nontumor mammary gland-derived cell lines (CRL7347, CRL7379, CRL7847 and MCF10a) the four analyzed breast cancer cell lines (MCF7, BT474, MDA-MB468 and ZR-75-1) express significantly higher levels of SF2/ASF correlated with higher levels of p31 S6K1 (Figure 1c) . A similar tumor-associated pattern was observed comparing four bladder cancer cell lines (5637, RT4, RT112 and T24) with HCV29 cells derived from normal, non-malignant ureteric epithelium (Figure 1d ). In addition, comparing transformed HeLa or HEK293 cells with normal, non-tumor-derived IMR-90, provided further support for the connection between transformation and high levels of SF2/ASF and p31 S6K1 (Figure 1d ). The following results prove the specificity of the analyzed band here for the p31 isoform: (1) in a wide variety of different cell types we confirm the correlation of the expression of SF2/ASF and p31 (Figures 1c and d) . (2) BT474 is a tumor-derived cell line with an S6K1 gene amplification (Karni et al., 2007) . We found all three protein bands (p85, p70 and p31) to be upregulated in this cell line (Figures 1c, e and f) . (3) Although using an N-terminal anti-S6K1 antibody allows the detection of p31, a C-terminal anti-S6K1 antibody only detects p85 and p70, but not p31, which is known to have a different C-terminal sequence (Figure 1e) . (4) We have performed S6K1-specific siRNA experiments in two different cell lines demonstrating that the bands representing the p85, p70 and p31 isoforms were affected (Figure 1f ).
It has already been shown in the past, that SF2/ASF and p31 are upregulated in breast cancer cell lines (Karni et al., 2007) . Using a different set of breast cancer cell lines and normal counterparts our presented data here confirm this correlation. In addition, for the first time we provide evidence that this deregulation could also be involved in bladder cancer development. Finally, these results prove that upregulation of SF2/ASF is always accompanied with high levels of p31 and that we have established conditions allowing the analysis of all three endogenous S6K1 proteins in human and murine cells.
Furthermore, these data show that IMR-90 cells can be used to study the endogenous regulation of the three S6K1 proteins. This is of importance, as we wanted to study the localization and regulation of the endogenous S6K1 proteins in a non-transformed, non-immortalized diploid primary human cell system showing no evidence for deregulated S6K1 expression (Figures 1d-f) . IMR-90 cells have the same DNA content as other normal primary human cells (see the comparison with human amniotic fluid cells in Figure 2a ), are commercially available to all colleagues in the field and can easily be cultivated with reasonable proliferation rates. Additionally, for the planned experiments it was necessary to prove that the here chosen IMR-90 cells can be cell cycle synchronized via serum deprivation and restimulation and can be used to perform nucleocytoplasmic fractionations of high purity (Figures 2a and b) .
Using IMR-90 fibroblasts we separated cytoplasmic and nuclear fractions, the latter was proven not to be significantly contaminated with cytoplasmic, mitochondrial or endoplasmatic reticulum proteins. Although p70 S6K1 can be detected in the cytoplasm and in the nucleus (predominantly cytoplasmic), p85 S6K1 was found to be cytoplasmic. The alternative splicing isoform p31 S6K1 was observed to be a nuclear protein (Figures 2b-e) . Since p85 is less abundant than p70, we next wanted to exclude that the reason why p85 does not appear in the nuclear fraction is just due to detection limits. (1) In Figure 2d we show a western blot localization experiment, in which the cytoplasmic/ nuclear protein loading ratio is 1:5 and p85 was not detectable in the nucleus, neither the total protein nor the phosphorylated form. (2) We performed an immunoprecipiation experiment (less unspecific protein background) analyzing fractionated IMR-90 with a cytoplasmic/nuclear protein loading ratio of 1:8. Again, we could not detect p85 in the nucleus under the used experimental conditions here (Figure 3a) . (3) This result was confirmed in mouse embryonic fibroblasts (MEFs) (Figure 3b) .
It was interesting to see that the S6K1-phosphorylated forms of mTOR and S6 could be detected in higher levels in the nucleus than in the cytoplasm (Figures 2e, 3a and 7f). In the future these localization patterns could be of interest for further investigations of both, the upstream regulators of these two proteins and their downstream targets. This is the first demonstration that in primary normal cells the three S6K1 proteins are differently localized and that alternative splicing of S6K1 can be a mechanism resulting in different nucleocytoplasmic localization of the proteins encoded by the one gene RPS6KB1.
Blocking mTOR activity causes delocalization of p70 S6K1, but is without effects on p85 and p31 localization p31 S6K1 does not contain the mTOR-mediated phosphorylation site T389 found in p70 S6K1, corresponding to T412 in p85 S6K1 (Figure 1b) , and accordingly cannot be detected via an anti-phospho T389 S6K1-specific antibody. Upon treatment with the mTOR-specific inhibitor rapamycin phosphorylation of p70 T389 and p85 T412 dissapeared, always accompanied by a shift to the faster migrating forms of these proteins (Figures 2c-e, 4a and b) . Furthermore, our data suggest but not necessarily prove that p31 is a phosphorylation target of mTOR: (1) treatment with the mTOR-specific inhibitor rapamycin triggers a p31 mobility shift (Figures 2c, d, 4a and b) . (2) mTOR is a cell cycle-regulated enzyme and the p31 mobility shift is cell cycle regulated ( Figure 4c) . (3) We have performed calf intestine alkaline phosphatase experiments showing that p31 is a phosphoprotein and that the rapamycin-sensitive mobility shift reflects phosphorylation ( Figure 4b ).
As described above, incubation with rapamycin induced a shift to the faster migrating form of p85 S6K1 in the cytoplasm and of p31 S6K1 in the nucleus. (a) Non-transformed, non-immortalized human IMR-90 fibroblasts were examined for chromosomal abnormalities via standard karyotyping procedures (upper panel) and cytofluorometrically analyzed for DNA content on a fluorescence-activated cell sorter (FACS). Freshly isolated and cultured human amniotic fluid-derived cells (hAFCs) served as a control for a normal, diploid DNA content and were analyzed in parallel (lower panel, left). Additionally, IMR-90 were serum deprived (0.2% serum for 48 h) and restimulated with 10% serum for 27 h. FACS analyses of so treated cells were performed to verify suitability of IMR-90 fibroblasts for cell synchronization and restimulation experiments (lower panel, right). (b) IMR-90 were separated into cytoplasmic and nuclear fractions and examined via immunoblotting. Purity of obtained fractions was proven by analyzing a panel of different subcellular marker proteins as indicated. Whole cell lysate from the same pool of cells was analyzed in parallel. In terms of purity, these data are representative for all fractionation experiments presented in this study. (c) Cytoplasmic/nuclear fractionation of IMR-90, treated with dimethyl sulfoxide (DMSO) or 100 nM rapamycin for 24 h, was performed. Equal amounts of fractions (cytoplasmic/nuclear protein loading ratio ¼ 1:1) were analyzed for the mTOR-phosphorylated forms of p85 and p70 S6K1 (upper panel) and for the total expression of p85, p70 and p31 S6K (lower panels) via iummunoblotting. Asterisks indicate non-related, cross-reactive bands. (d) Experiments were performed as described in (c) except that the amount of nuclear protein loaded was five times higher compared with the amount of cytoplasmic protein loaded (cytoplasmic/nuclear protein loading ratio ¼ 1:5). Asterisks indicate non-related, cross-reactive bands. (e) Equal amounts of cytoplasmic and nuclear fractions of rapamycin-treated IMR-90 cells (100 nM for 24 h) were analyzed for phosphorylated and total forms of p85 and p70 S6K1 and for phosphorylated and total forms of the S6K1 substrates ribosomal protein S6 and mTOR via immunoblotting. Fibrillarin (a marker protein specifically expressed in the nucleolus) and atubulin serve as fractionation and loading controls. The asterisk indicates non-related, cross-reactive bands.
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Figure 3 Cytoplasmic localization of p85 S6K1 in human amd murine fibroblasts. (a) p85 and p70 S6K1 were immunoprecipitated from IMR-90 cytoplasmic and nuclear fractions at indicated ratios using an anti-p70 S6K1 antibody and were analyzed for their expression via immunoblotting (IP, upper panel; C(1X) corresponds to 60 mg of cytoplasmic protein lysate, N(1X) and N(8X) correspond to 60 and 480 mg of nuclear protein lysate, respectively, used for immunoprecipitation). Reactions in which the precipitating antibody was omitted were analyzed in parallel and serve as a negative control. In addition, supernatants of precipitates were examined for the depletion of p85 and p70 S6K1, for the expression of fractionation/loading controls atubulin and fibrillarin and for the S240/ 244 phosphorylated form of the S6K target S6. The asterisk indicates an immunoreactive band originating from the previous fibrillarin detection (IP-SN, lower panel). (b) TSC2 þ / þ MEFs were fractionated and cytoplasmic and nuclear fractions of indicated protein loading ratios were examined for p85 and p70 S6K1 expression via immunoblotting. atubulin and fibrillarin were co-analyzed and serve as a control for proper fractionation and loading. Figure 4 Altered gel migration properties of the phosphoprotein p31 S6K1 under growth inhibitory and stimulated conditions. (a) IMR-90 fibroblasts were treated with 100 nM rapamycin for indicated times. Whole cell lysates were prepared and analyzed for the phosphorylation status of p85 and p70 S6K1 at T412 and T389, respectively (upper panel) and the expression level of p85, p70 and p31 S6K1 (lower panel) via immunoblotting using indicated antibodies. Asterisks indicate non-related, cross-reactive bands. (b) IMR-90 cells were either left untreated or were incubated with 100 nM rapamycin or DMSO (vehicle control) for 1 h. Whole cell lysates of so treated cells were examined for the expression level of p85, p70 and p31 S6K1 and for p70 S6K1 phosphorylation at T389. In parallel, lysates of logarithmically growing IMR-90 derived from the same pool of cells were treated with or without CIAP (calf intestine alkaline phosphatase) for 1 h at 37 1C and were co-analyzed in the same immunoblotting experiment. The asterisk indicates nonrelated, cross-reactive bands. (c) IMR-90 were either grown under basal growth conditions (log for logarithmically growing) or serum deprived in medium containing 0.2% serum for 48 h and serum restimulated for additional 9 h. So treated cells were harvested, stained with propidiumiodide and cytofluorometrically analyzed for DNA content. In addition, total protein was extracted and lysates were examined for the expression of cell cycle marker proteins cyclin A, cyclin D1 and p27 (upper panel). Cells grown under inhibitory or stimulated conditions as described were examined for the phosphorylation of p85 and p70 S6K1 at T412 and T389, respectively, and for p31 S6K1 expression (lower panel).
However, the localization of these two proteins remained unchanged (Figures 2c and d) . Rapamycin treatment also caused a shift to the faster migrating form of p70 S6K1 in the cytoplasm, but triggered complete loss of this protein in the nucleus (Figures 2c-e) . Taken together, these data demonstrate that although mTOR is not involved in the localization of p85 and p31, p70 S6K1 nucleocytoplasmic localization is stringently controlled via this kinase.
The findings described above suggest that only phosphorylated p70 S6K1 is localized to the nucleus. To allow the detection of the different phosphorylated/ hyperphosphorylated p70 forms a, b, g, d (Cheatham et al., 1995; Kanazawa et al., 2004) we next resolved IMR-90 protein fractions by 7.5% SDS gel conditions. These experiments revealed that indeed only the hyperphosphorylated forms of p70 S6K1 (corresponding to T389 phosphorylated p70 S6K1) localize to the nucleus. Rapamycin treatment confirmed again that hypophosphorylated p70 remains in the cytoplasm but completely disappears from the nucleus (Figure 5a ).
All rapamycin experiments described so far were longterm treatments for 24 h known to also trigger a pronounced cell cycle arrest of IMR-90 cells. The 1 h short term incubation with rapamycin does not affect the cell cycle of these cells (Rosner and Hengstschla¨ger, 2008; Rosner et al., 2009) . Accordingly, it was of interest to investigate whether the obtained effects on p70 S6K1 localization were a direct consequence of mTOR kinase activity or were associated with putative secondary effects due to cell cycle arrest. To answer this question we performed 1 h short-term experiments using different concentrations of the mTOR-inhibitor rapamycin. We found the effects on p70 localization to be titratable depending on the remaining mTOR activity and to be independent of any mTOR-mediated cell cycle effects (Figure 5b ).
Loss of tuberin triggers increased nuclear p70 S6K1 As described above, blocking mTOR activity triggers delocalization of p70 S6K1, but is without effects on p85 and p31 localization. We next wanted to test whether activation of mTOR can induce nuclear p70 localization. To investigate this question we decided to modulate the activity of tuberin, which is the main negative regulator of mTOR (see introduction).
Analyses using TSC2 þ / þ (MEFs) confirmed that p85 is cytoplasmic whereas p70 can be detected in both, the cytoplasm and the nucleus. Increased mTORmediated phosphorylation of p70 and p85 (studied via the phospho-T389/T412-specific antibody and the appearance of the slower migrating protein forms) upon loss of TSC2 in TSC2 À/À cells induces nuclear localization of p70 S6K1 but is without effects on p85 localization (Figures 6a and b) . Short-term serum Figure 5 Rapamycin-mediated inhibition of p70 S6K1 phosphorylation prevents its nuclear localization. (a) IMR-90 cells treated with 100 nM rapamycin for 24 h and separated into cytoplasmic and nuclear fractions were examined for the distribution of phosphorylated and total forms of p85 and p70 S6K1 via western blotting. For better visualization of the phosphorylation-mediated S6K1 gel shift duplicates of lysates were resolved by 7.5% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were cut, separately incubated with antibodies as indicated and remerged for chemiluminescence detection allowing direct comparison of cytoplasmic and nuclear p70 S6K1 phosphorylated at multiple sites (a, b, g and d forms of p70 S6K1, left panels) and p70 S6K1 phosphorylated at T389 (g and d forms of p70 S6K1, right panels). Different exposures have been merged together to facilitate interpretation. The asterisk indicates non-related, cross-reactive bands. (b) Cells were treated with low doses of rapamycin for 1 h and examined for phopshorylated p85 and p70 S6K1 in whole cell lysates (left panel) and for distribution of total p85 and p70 S6K1 in subcellular fractions (right panels). Co-analyses of atubulin and topoIIb serve as fractionation and loading controls.
starvation triggers downregulation of mTOR activity accompanied by loss of nuclear p70 S6K1 localization in TSC2 þ / þ cells (again without effects on p85 localization). The observation that p70 S6K1 localization is insensitive to serum starvation in TSC2 À/À cells proves this serum-mediated regulation to be tuberin-dependent. (Figures 6a and b) . These results in murine cells were confirmed in human cells by downregulation of endogenous tuberin via TSC2-specific siRNA treatment of IMR-90 cells (Figure 6c) .
Furthermore, short-term restimulation of starved MEFs revealed that serum can induce nuclear p70 S6K1 localization. Blocking mTOR activity, either by the mTOR-inhibitor rapamycin or the PI3K-inhibitor wortmannin showed that this serum-induced nuclear localization of p70 depends on the PI3K/TSC2/mTOR pathway (Figure 6b ). In summary, these results demonstrate (1) that the nucleocytoplasmic localization of p85 and p70 is the same in murine embryonic fibroblasts and in primary human fibroblasts (IMR-90), (2) that in both cells induction of mTOR activity via downregulation of tuberin induces nuclear localization of p70, but is without effects on p85 localization, (3) that serum regulates p70 localization, but not the localization of p85, in a PI3K/TSC2/mTOR-dependent manner.
mTOR-mediated phosphorylation of p70 S6K1 at T389 is essential for its nuclear localization To determine whether phosphorylation at T389 or the kinase activity of p70 S6K1 is required for nuclear translocation (or merely correlates with nuclear translocation), we performed experiments with different p70 S6K1 mutants (Figure 7a) . First, we proved that wildtype p70 S6K1, ectopically expressed in primary IMR-90 cells, is regulated and localized comparable to the Figure 6 Loss of TSC2 induces p70 S6K1 nuclear localization. (a) TSC2 knockout MEFs were grown in medium containing 10% serum (basal) or were starved in medium without serum (0% serum) for 12-16 h (starvation). Whole cell lysates were examined for the expression of tuberin, phosphorylated p85 and p70 S6K1 and phosphorylated S6 (upper panel, left) . Additionally, DNA content was determined on a flowcytometer (lower panel, left). Cytoplasmic/nuclear fractions of the same pool of cells were analyzed for distribution of phosphorylated and total forms of p85 and p70 S6K1 via immunoprecipitation and immunoblotting (IP:a-p70 S6K1, IB:a-p70 S6K1 T389 and a-p70 S6K1) (right panels). (b) For short-term serum stimulation experiments TSC2 MEFs were starved overnight as described above and restimulated with 10% serum for 30 min. Where indicated, rapamycin or wortmannin was added 30 min before restimulation at a concentration of 100 nM. Whole cell lysates were examined for tuberin and phosphorylated and total forms of p70 S6K1 and S6 (left panel). Subcellular distribution of p70 S6K1 was analyzed in cytoplasmic and nuclear fractions (cytoplasmic:nuclear protein loading ratio ¼ 1:5) via immunoprecipitation and immunoblotting (IP:a-p70 S6K1, IB:a-p70 S6K1 T389 and a-p70 S6K1). Equal loading and purity of fractions was proven by co-analysing supernatants of precipitates for atubulin and topoIIb (right panel). (c) Experiments described in (a) were repeated with IMR-90 cells transfected with TSC2-specific or non-targeting siRNAs (si control). Whole cell lysates and subcellular fractions were investigated for the expression of indicated proteins via immunoblotting (left panel) or via immunoprecipitation and subsequent immunoblotting (IP:a-p70 S6K1, IB:a-p70 S6K1 T389 and a-p70 S6K1) (right panel). (Figures 7b and c) . The S6K1-DTOS (S6K1-F5A) mutant, which cannot bind to raptor and is therefore neither phosphorylated at T389 (with other S6K1-phosphorylation sites remaining largely unaffected by the mutation) nor exerts kinase activity (Schalm and Blenis, 2002; Holz et al., 2005; Figures 7d and e), exhibits diminished nuclear localization compared to the wild-type protein (Figures 7d and e) . The kinase-dead mutant S6K1-KD (S6K1-K100R, mutated in the ATP binding site), which in addition to its loss of kinase activity is also not T389 phosphorylated (Cheatham et al., 1995; Holz et al., 2005;  Figure 7e ), also exhibited diminished nuclear localization (Figure 7e ). Vice versa, the constitutively active, rapamycin-resistant Figures 7b-g co-analyses of atubulin and fibrillarin have been included and serve as fractionation and loading controls). (h) Brief overview summarizing the main features of studied S6K mutants with respect to phosphorylation status at T389, in vitro kinase activity, eIF3-PIC (translation preinitiation complex) binding and nuclear localization (ND, not determined). Presented data originate from this study and studies previously published and referenced/discussed in the text.
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M Rosner and M Hengstschläger mutant S6K1-RR (S6K1-F5A-E389-R3A; Schalm et al., 2005) , which remains to be phosphorylated at T389 upon rapamycin treatment (Figure 7f ), retains its nuclear localization compared with the wild-type protein (Figure 7f ). In addition, we found a p70-S6K1-truncated protein without the N-terminal TOS motif, without the C-terminal autoinhibitory domain (its loss partially reverts the negative effects of loss of functional TOS motif in respect to T389 phosphorylation and kinase activity) and without the PDZ-binding motif (Cheatham et al., 1995; Weng et al., 1995; Schalm et al., 2005) to exhibit proper localization (Figure 7g ). Taken together, these findings demonstrate that the mTOR-dependent phosphorylation of p70 S6K1 at T389, respectively the p70 S6K1 kinase activity, determines p70 S6K1 nucleocytoplasmic localization (Figure 7h ).
The nucleocytoplasmic p70 S6K1 localization is regulated throughout the cell cycle via TSC2/mTOR
The results presented in Figure 6 demonstrate that shortterm (30 min) serum restimulation triggers p70 S6K1 nuclear localization in a PI3K/TSC2/mTOR-dependent manner. As 30 min restimulation does not induce G0 cells to enter the cell cycle, these observations prove this regulation to be a direct consequence of mTOR activity rather than of secondary cell cycle effects.
The results made it interesting to investigate the cell cycle regulation of the nuclear localization of p70 S6K1. IMR-90 cells were synchronized in G0/G1 via serum deprivation. Flow cytometric analyses of the amount of G0/G1, S and G2/M phase cells and western blot analyses of typically cell cycle regulated proteins, such as jun, cyclin D1, cyclin A or p27, were performed to qualify the re-entering of these cells upon serum stimulation (Figure 8a ).
Although cytoplasmic p70 S6K1 can be detected in all phases of the cell cycle, this protein becomes nuclear only in mid G1 phase. Comparing the pattern of total p70 S6K1 protein with the cell cycle regulation of p70 S6K1 protein phosphorylated at T389 demonstrated that in G0/G1 hypophosphorylated protein exists in the cytoplasm. However, in the nucleus total p70 protein cannot be detected before it becomes phosphorylated via mTOR (Figure 8a) . Furthermore, induction of mTOR activity via a combined approach of serum restimulation and TSC2-specific siRNA treatment is able to induce the nuclear localization of phosphorylated p70 S6K1 in G0/ G1 (Figure 8b ).
These findings confirm that the mTOR-dependent phosphorylation induces nuclear localization of p70 S6K1. In addition, we report for the first time that the nucleocytoplasmic localization p70 is strictly cell cycledependent and that the TSC2/mTOR pathway is responsible for this regulation.
Discussion
The PI3K/TSC2/mTOR cascade is known to have important roles in many cytoplasmic and nuclear processes, including, for example, translation, ribosome biogenesis or transcription. Deregulation of mTOR is involved in tumor development, differentiation processes, apoptosis and cell size control (Yang and Guan, 2007; Wang and Proud, 2009 ). The specific roles of the different mTOR targets for these different effects are poorly understood. To allow a better understanding of these regulations it is required to examine the temporal and spatial dynamics of endogenous mTOR targets. Compartmentalization could keep different upstream regulators and downstream effectors of mTOR in different localizations allowing coordinated regulations in response to different stimuli or throughout cellular processes, such as differentiation, apoptosis or cell cycle (Shaw, 2008; Sengupta et al., 2010) .
In this study we compared the nucleocytoplasmic localization of the different isoforms of S6K1, a major target of mTORC1. This is of special interest as a variety of nuclear and cytoplasmic substrates of S6K1 proteins have been described (Ruvinsky and Meyuhas, 2006; Meyuhas and Dreazen, 2010; Fenton and Gout, 2011) . Using primary non-immortalized, non-transformed human fibroblasts we found p85 to be cytoplasmic, p31 to be nuclear and p70 S6K1 to be localized to both compartments. This is the first comparative analysis of the nucleocytoplasmic localization of all three S6K1 proteins. The S6K1 isoform p31 is generated via alternative splicing mediated by SF2/ASF. It was reported that p70 S6K1 has little oncogenic potential, but the alternatively spliced p31 S6K1 is sufficient to cause cellular transformation (Karni et al., 2007) . These findings on this dramatic difference between the two S6K1 isoforms made it interesting to investigate how the properties of S6K1 may be altered as a consequence of the splicing switch. We here report that this splicing switch triggers different localization of the oncogenic and the non-oncogenic S6K1 isoforms. Taken together, alternative splicing via SF2/ASF results in an oncogenic smaller p31 S6K1 isoform 2, which in contrast to the non-oncogenic p70 S6K1 isoform 1 exclusively localizes to the nucleus. SF2/ASF and p31 have been reported to be upregulated in breast cancer cell lines (Karni et al., 2007) . Using a different set of breast cancer cell lines and normal counterparts we confirmed this observation in the presented study here. Analyzing a set of bladder cancer cell lines we here provide first evidence that overexpression of SF2/ASF accompanied by induced levels of p31 S6K1 could also be involved in the molecular development of bladder cancer.
Although this is the first analysis of the nucleocytoplasmic localization of p31, the localization of p70 and p85 has already been investigated in the past. In agreement with our data, p70 S6K1 has always been localized to both, cytoplasm and nucleus, but the underlying regulating mechanism remained elusive (Coffer and Woodgett, 1994; Kim and Kahn, 1997; Kim and Chen, 2000 ). An earlier report described growth factor-dependent fluctuation of S6K1 localization. This report could not investigate the later discovered p31 isoform and moreover did not experi-mentically differentiate between the p70 and p85 proteins (Edelmann et al., 1996) .
The S6K1 isoforms p70 and p85 are well known to be targets of mTOR-mediated phosphorylation (see Introduction). Data presented in this report suggest but not necessarily prove that p31 is also a phosphorylation target of mTOR. We found rapamycin treatment to trigger a mobility shift of p31 in western blot analyses. This p31 mobility shift was proven to be the consequence of protein phosphorylation and is cell cycleregulated correlating with mTOR activity.
However, inhibiting endogenous mTOR activity via rapamycin and activation of mTOR in TSC2 À/À MEFs and in IMR-90 human fibroblasts treated with TSC2-specific siRNAs revealed that mTOR regulates the nucleocytoplasmic localization of p70, but not of p31 and p85 S6K1. Activation of mTOR induces nuclear p70 S6K1 localization and inhibition of mTOR leads to loss of nuclear p70. We found that only mTORmediated hyperphosphorylated p70 S6K1 is located to the nucleus. This is the first demonstration that mTOR not only regulates p70 S6K1 activity, but also its localization. As we and other colleagues have found little to no mTORC1 kinase complex in the nucleus (Rosner and Hengstschla¨ger, 2008; Sancak et al., 2008) , it is very likely that mTOR-mediated phosphorylation of p70 S6K1 in the cytoplasm triggers its localization into the nucleus. This notion is further supported by our Figure 8 Cell cycle-dependent nucleocytoplasmic distribution of phosphorylated p70 S6K1 is regulated by TSC2. Non-treated IMR-90 or IMR-90 with modulated TSC2 expression were synchronized in G0/G1 via serum deprivation and serum restimulated to re-enter the cell cycle. (a) Schematic outline of the synchronization procedure. Briefly, cells growing under full serum conditions (10% serum) for 24-72 h were serum deprived in medium containing 0.2% serum for 48 h and serum restimulated (10% serum) for additional 36 h. At indicated time points of restimulation cells were harvested and cytofluorometrically analyzed for DNA content. Representative DNA profiles and the relative amount of cells in different cell cycle phases are presented. In addition, whole cell lysates were prepared and examined for the expression level of cell cycle regulated proteins jun, cyclin D1, cyclin A and p27 via immunoblotting. Subcellular fractions of the same pool of cells were analyzed for the distribution of phosphorylated and total p70 S6K1. Equal loading and purity of fractions was proven by co-analysing atubulin and topoIIb. (b) Experiments were performed as described in (a) except that cells were transfected with TSC2-specific or non-targeting siRNAs 48 h before restimulation. Also compare schematic outline of the procedure presented. At indicated time points, cells were harvested and investigated for DNA distribution and expression of tuberin, cyclin D1, atubulin and phosphorylated and total p70 S6K1. In addition, cytoplasmic and nuclear fractions were prepared and analyzed for T389 phosphorylated p70 S6K1 via immunoblotting.
finding that during restimulation of G0 cells into the cell cycle mTOR-mediated phosphorylation of p70 S6K1 in the cytoplasm occurs at earlier time points than it is detectable in the nucleus. Furthermore, performing short-term serum starvation and restimultation experiments we here demonstrate that the growth factormediated localization of p70 S6K1 is regulated via PI3K/TSC2/mTOR. (1) Serum starvation triggers downregulation of mTOR activity accompanied by loss of nuclear p70 S6K localization. (2) Our finding that p70 S6K1 localization is insensitive to serum starvation in TSC2 À/À cells demonstrates this regulation to be tuberin dependent. (3) All these results obtained in murine cells were confirmed in human cells by downregulation of endogenous tuberin via TSC2-specific siRNA treatment. (4) Blocking mTOR activity, either by the mTOR-inhibitor rapamycin or the PI3K-inhibitor wortmannin again showed that the serum-induced nuclear localization of p70 depends on the PI3K/TSC2/ mTOR pathway.
The analyses of a variety of different p70 S6K1 mutants provided more detailed insights into the relevance of the different p70 S6K1 protein motifs for nucleocytoplasmic localization (summarized in Figure 7h ). Studying two mutants, which cannot be phosphorylated at T389, and one T389 phosphorylation-mimicking mutant demonstrated the requirement of this site-specific phosphorylation for p70 S6K1 nuclear localization. These ectopic expression experiments of different mutants further revealed that both, the TOS motif of p70 S6K1 (essential for binding to the mTORC1 component raptor) and the ATP binding site are indispensable for proper p70 localization. In addition, we found a p70-S6K1-truncated protein without the N-terminal TOS motif, without the C-terminal autoinhibitory domain (its loss partially reverts the negative effects of loss of functional TOS motif in respect to T389 phosphorylation and kinase activity) and without the PDZ binding motif to exhibit proper localization. From the here obtained results it appeared that the latter mutant missing the PDZ binding motif, earlier shown to be involved in the binding of p70 S6K1 to neurabin (reviewed in Fenton and Gout, 2011) , even exhibited an increased nuclear localization (Figure 7g) . Further experiments are warranted to investigate a putative role of this motif in cytoplasmic retention of p70 S6K1.
It was earlier reported that unphosphorylated p70 S6K1 binds to a protein complex named eIF3-PIC (translation preinitiation complex). This complex has been discussed to function as a scaffold on which mTOR phosphorylates p70 S6K1 at T389, what triggers dissociation of p70 S6K1 from eIF3-PIC (Holz et al., 2005) . We found that two p70 S6K1 mutants, earlier shown to bind this complex, exhibit diminished nuclear localization, whereas one p70 mutant defective in binding this protein complex (Holz et al., 2005) , shows induced nuclear localization (Figure 7) . On the one hand, these data could be interpreted to only be a consequence of the correlation of eIF3-PIC binding and S6K1 phosphorylation taking into account that we demonstrate this regulation of phosphorylation to be responsible for p70 nuclear localization. On the other hand, one could speculate that binding to eIF3-PIC might have an active role in p70 S6K1 cytoplasmic retention. In future, it will be of interest to clarify this issue.
It was earlier reported that phosphorylation of p70 S6K1 via CK2 protein kinase promotes its export from the nucleus, but this regulation is not responsible for the above described growth factor-dependent fluctuation of nucleocytoplasmic p70 localization (Panasyuk et al., 2006) .
In the past, two arguments have often been cited to support the notion that p85 S6K1 is a nuclear protein: the first 23 amino acids contain a suggested nuclearlocalization-signal and an immunocytochemical approach using a specific antibody provided evidence for nuclear localization (Reinhard et al., 1994) . However, we show here that p85 S6K1 is not a nuclear but a cytoplasmic protein in non-transformed, non-immortalized primary human cells and in MEFs. During the course of our project, a report has been published describing a similar observation on p85 localization (Kim et al., 2009) . Here it is important to note that earlier immunocytochemical studies could have used antibodies, which must be clarified for their potential to differentiate between the three different S6K1 isoforms.
In long-term restimulation experiments we further found that re-entry of G0 cells into the cell cycle triggers nuclear localization of p70 S6K1 in an mTORdependent manner. Furthermore we found that cytoplasmic p70 S6K1 protein can be detected throughout the entire cell cycle but p70 does not enter the nucleus before mid G1 phase. We demonstrated that induction of mTOR activity via TSC2-specific siRNA treatment is able to induce the nuclear localization of phosphorylated p70 S6K1 in G0/G1. These data prove that the cell cycle-dependent nuclear localization of p70 S6K1 is mediated by its phosphorylation at T389 via mTOR. For a better understanding and for further investigations of the regulation of the different cytoplasmic and nuclear targets of p70 S6K1, the discovery of this cell cycle control is of highest relevance.
Deregulation of mTOR is a hallmark of many human cancers and genetic diseases. Owing to their antiproliferative and immunosuppressive potential, rapamycin and related drugs (analogs) are being currently evaluated in many clinical trials for a variety of different cancers, for diabetes and as parts of specific transplant immunosuppresion regimens (Chiang and Abraham, 2007; Plas and Thomas, 2009 ). Especially as it already became evident that different tumors (as well as different patients) respond differently to rapamycin, a more detailed understanding of the spatial and temporal intracellular effects of rapamycin-induced mTOR inhibition is critical for this drug to most effectively be used in the clinic. Our observation that rapamycin triggers different effects on the three S6K1 forms in the cytoplasm and in the nucleus might be of relevance for the future usage of this mTOR-inhibitor in clinical trials for different cancer syndromes and human genetic diseases involving deregulation of different S6K1 proteins.
Materials and methods

Cells
IMR-90 (#CCL-186, American Type Culture Collection (ATCC), Wesel, Germany) are fetal lung-derived, non-transformed, non-immortalized human diploid fibroblasts with finite lifetime and were obtained at passage number 10 (population doubling 25). To avoid potential effects due to cellular senescence, cells were grown for no more than eight additional passages (p47 total population doublings) and were regularly analyzed by standard karyotyping to confirm a normal diploid karyotype. Mammary gland-derived cell lines analyzed in this study include CRL7347, CRL7379, CRL7847, all obtained from apparently normal tissue of patients with a carcinoma of the breast, MCF10a, an immortalized breast cell line from a patient with fibrocystic disease, and MCF7, BT474, MDA-MB 468 and ZR-75-1, four established breast cancer cell lines. Urothelial cell lines used are HCV29, derived from normal, non-malignant ureteric epithelium of a patient with transitional cell carcinoma and bladder tumor-derived cell lines 5637, RT4, RT112 and T24. In addition, HeLa cervical adenocarcinoma cells, HEK293 human embryonic kidney cells, NIH3T3 mouse fibroblasts, immortalized MEFs (TSC2 þ / þ and TSC2
À/À
) and primary human amniotic fluid cells (hAFCs) were analyzed. All cells are available from ATCC, except two lines of the collection of urothelial cell lines (Knowles et al., 2003) and the TSC knockout MEFs used here, kindly provided by Drs M Knowles (Leeds, UK) and D Kwiatkowski (Boston, MA, USA), respectively. Primary hAFCs were obtained from amniocentesis performed for routine prenatal diagnosis. Usage of hAFCs was approved by the ethics committee of the University of Vienna (project number: 036/2002). All cells were grown at 37 1C and 5% CO 2 . Media used for cell cultivation were the following: Dulbecco's modified Eagle's medium (PAA, Pasching, Austria) at 4.5 g/l glucose for IMR-90, HeLa, HEK293, NIH3T3, TSC MEFs, CRL7347, CRL7379, CRL7847 and MCF7. Dulbecco's modified Eagle's medium/F12 (Invitrogen, Lofer, Austria) (supplemented with EGF and insulin, both form Sigma, Vienna, Austria) for MCF10a. RPMI/NCTC135 (Invitrogen) (supplemented with insulin) for BT474, McCoy's Medium (PAA) for MDA-MB 468, RT4 and T24, RPMI (PAA) for ZR-75-1 and urothelial cell lines HCV29, 5637 and RT112 and Ham's F10 (Invitrogen) (supplemented with Ultroser G, PALL, Vienna, Austria) for hAFCs. All media were supplemented with 10% calf serum, 2 mM L-Glutamine, antibiotics (60 mg/l penicillin, 100 mg/l streptomycin sulfate) and additives as indicated.
Cell culture and reagents For short-term serum stimulation experiments cells were starved in growth medium without serum (0% serum) for 12-16 h and then treated and stimulated as indicated. For G0/G1 cell synchronization experiments, IMR-90 fibroblasts at passage number 15 were deprived of serum in growth medium containing 0.2% serum for 48 h. Cells were stimulated to re-enter the cell cycle by the addition of 10% serum for another 36 h. Experiments with the mTOR inhibitor rapamycin or the PI3K inhibitor wortmannin (both Calbiochem, La Jolla, CA, USA) were performed in the absence (DMSO vehicle control) or presence of the drug at indicated concentrations. For cytofluorometric DNA analyses trypsinized cells were fixed by rapid submersion in ice-cold 85% ethanol. After overnight fixation at À20 1C, DNA was stained with 0.25 mg/ml propidium iodide, 0.05 mg/ml RNase, 0.1% Triton X-100 in citrate buffer, pH 7.8. DNA distribution of a total of 2 Â 10 4 -4 Â 10 4 cells per sample was analyzed on a Beckton Dickinson FACScan (Becton Dickinson, San Jose, CA, USA). Karyotyping of primary IMR-90 fibroblasts was performed according to standard procedures. Chromosome banding was produced by means of a conventional 550-band trypsin-Giemsa analysis (GTG) and a significant number of metaphases were analyzed for numerical and structural chromosome aberrations (Hengstschla¨ger et al., 2001) .
RNA interference
The siRNA transfection experiments were performed using Lipofectamine 2000 transfection reagent (TSC2-specific siRNAs) or Lipofectamine RNAiMAX (S6K1-specific siRNAs) (both Invitrogen) following the guidelines provided by the manufacturer. Pooled siRNAs specifically targeting human TSC2 or human S6K1 (Dharmacon, ON-TARGETplus SMART pool reagents, Dharmacon, Lafayette, CO, USA) were delivered to the cells at a final concentration of 100 nM and 50 nM, respectively. A pool of four non-targeting siRNAs was used as a control for non-sequence-specific effects. After 96 h of incubation, cells were harvested for analyses (Rosner et al., 2009 (Rosner et al., , 2010 . Combined approaches of cell synchronization and siRNA transfection are outlined in the corresponding Figure and Plasmid constructs and transfection HA-S6K1 constructs used in this study were generated in the laboratories of Drs J Blenis and J Avruch and were purchased via Addgene (Cambridge, MA, USA): HA-S6K1 wild type, HA-S6K1-DTOS (S6K1-F5A), HA-S6K1-KD (HA-S6K1-K100R, kinase-dead), HA-S6K1-RR (HA-S6K1-F5A-E389-R3A, rapamycin-resistant/constitutively active) and HA-S6K1-DNTDCT (deletion of the N-and C-termini retaining the kinase domain and the hydrophobic motif at T389). Plasmids were transfected into IMR-90 fibroblasts using Lipofectamine 2000 transfection reagent.
Preparation of whole cell lysates and cytoplasmic/nuclear fractions Whole cell lysates containing both, cytoplasmic and nuclear proteins, were prepared by physical disruption of cell membranes by repeated freeze and thaw cycles. Briefly, cells were washed with PBS and harvested by trypsinization. Pellets were washed twice with ice-cold PBS and lysed in buffer A containing 20 mM Hepes, pH 7.9, 0.4M NaCl, 25% glycerol, 1 mM EDTA, 0.5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM NaF, 0.5 mM Na 3 VO 4 supplemented with 2 mg/ml aprotinin, 2 mg/ml leupeptin, 0,3 mg/ml benzamidinchlorid, 10 mg/ml trypsininhibitor by freezing and thawing. Supernatants were collected by centrifugation at 20 000 g for 20 min at 4 1C. For cytoplasmic and nuclear fractionation cell pellets were lysed in five packed cell volume buffer F1 containing 20 mM Tris-HCl, pH 7.6, 50 mM 2-mercaptoethanol, 0.1 mM EDTA, 2 mM MgCl 2 , 1mM phenylmethylsulfonyl fluoride supplemented with protease inhibitors (2 mg/ml aprotinin, 2 mg/ml leupeptin, 0,3 mg/ml benzamidinchlorid, 10 mg/ml trypsininhibitor) for 2 min at room temperature and subsequent incubation on ice for 10 min. Thereafter NP-40 was added at a final concentration of 1% (v/v) and lysates were homogenized by passing through a 20-gauge needle or equivalent through a 200 ml tip for three times. Nuclei were pelleted by centrifugation at 600 g for 5 min at 4 1C and supernatant containing cytoplasmic proteins was collected and stored at À80 1C. Remaining nuclei were washed three times in buffer F1 containing 1% NP-40. Pellets of pure nuclei were lysed in buffer containing 20 mM Hepes, pH 7.9, 0.4M NaCl, 25% glycerol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 0.5 mM dithiothreitol, supplemented with protease inhibitors by repeated freezing and thawing. Supernatants containing soluble nucleic proteins were collected by centrifugation at 20 000 g for 20 min Rosner and Hengstschla¨ger, 2008) .
Phosphatase treatment
For dephosphorylation of protein extracts cells were lysed in calf intestine alkaline phosphatase buffer containing 20 mM T, pH 8.0, 150 mM NaCl, 1 mM MgCl 2 , 1 mM dithiothreitol, 0.5% Triton X-100 supplemented with protease inhibitors (Shin et al., 2005) . Lysates were treated with or without 0.4 units of calf intestine alkaline phosphatase (Promega, Mannheim, Germany) per mg protein for 1 h at 37 1C. Reactions were stopped by adding phosphatase inhibitors (1 mM Na 3 VO 4 , 50 mM NaF) and boiling in SDS sample buffer at 95 1C for 5 min.
Immunoprecipitation and immunoblotting
In some cases where indicated, S6K1 was immunoprecipitated from total lysates or subcellular fractions before immunoblotting. For immunoprecipitation crude cell extracts (150 mg of total lysates or 350 mg of cytoplasmic and nuclear fractions) were diluted in NP-40-containing total cell lysis buffer and
